NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: DiNAQOR's Strategic Leadership Appointments and Company Expansion
TL;DR
DiNAQOR AG appoints Dr. Christian Thirion as CEO of DiNATEQ AG and Group Chief Strategy Officer, leveraging his proven track record to accelerate partnerships and commercial success in advanced therapies.
DiNAQOR AG strengthens its leadership with Dr. Christian Thirion overseeing strategy and Dr. Josef El Andari as CSO, focusing on translating closed-loop perfusion technology into clinical applications.
These appointments at DiNAQOR AG aim to advance precision delivery technologies for genetic therapies, potentially improving treatments for organ-specific diseases and addressing unmet medical needs.
Dr. Christian Thirion, who built Sirion Biotech into a global leader before its acquisition, now leads DiNATEQ AG's innovative closed-loop perfusion platform for therapeutic delivery.
Found this article helpful?
Share it with your network and spread the knowledge!
DiNAQOR AG announced strategic leadership appointments that strengthen its position as a life science company builder, including Dr. Christian Thirion as CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer, and Dr. Josef El Andari as Chief Scientific Officer of DiNAQOR AG.
Dr. Christian Thirion was appointed as Chief Executive Officer and Delegate of the Board of Directors of DiNATEQ AG, and he also assumes the newly created role of Chief Strategy and Business Development Officer of DiNAQOR AG.
Dr. Thirion brings more than two decades of entrepreneurial and executive leadership experience in life sciences, having founded and led Sirion Biotech as CEO, building it into a global market leader in viral vector engineering and AAV-based gene delivery before its acquisition by PerkinElmer.
DiNATEQ AG is a recently established DiNAQOR spin-out focused on the clinical translation of the closed-loop loco-regional perfusion (LRP) delivery platform.
Dr. Josef El Andari was appointed as Chief Scientific Officer of DiNAQOR AG, having been with the company for more than four years and playing a central role in advancing its scientific platforms.
DiNAQOR is a life science company builder focused on creating, scaling, and partnering next-generation biotechnology ventures by enabling the use of advanced, human-relevant nonclinical testing methods.
The announcement was made on December 22, 2025, from Zurich/Schlieren, Switzerland, through NEWMEDIAWIRE.
Johannes Holzmeister stated that Dr. Thirion is 'a rare combination of visionary entrepreneur, disciplined operator, and trusted partner to global pharmaceutical companies' and that his appointment significantly strengthens DiNAQOR's ability to build companies, execute partnerships, and translate breakthrough technologies into clinical and commercial success.
Dr. Thirion stated that DiNAQOR has built an exceptional ecosystem for turning scientific innovation into impactful biotechnology companies, and he is excited to lead DiNATEQ and help shape DiNAQOR's long-term strategy, forge pharmaceutical partnerships, and continue building companies that address significant unmet medical needs.
Curated from NewMediaWire
